Reference
Gatti M, et al. Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19. British Journal of Clinical Pharmacology : 8 Jul 2020. Available from: URL: http://dx.doi.org/10.1111/bcp.14459
Rights and permissions
About this article
Cite this article
Identification of serious, unpredictable adverse events with tocilizumab. Reactions Weekly 1813, 6 (2020). https://doi.org/10.1007/s40278-020-80763-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-80763-1